Alexander et al reported the Lung Cancer Prognostic Index (LCPI) for evaluating a patient with non-small-cell lung cancer (NSCLC). This can help to recognize a patient who may require more aggressive management. The authors are from multiple institutions in Australia.
Patient selection: non-small-cell lung cancer (NSCLC)
Parameters:
(1) stage
(2) histologic type (adenocarcinoma, squamous cell, large cell, NOS)
(3) presence of a proven actionable mutation (EGFR, ALK, KRAS)
(4) ECOG performance status
(5) smoking history
(6) respiratory comorbidity
(7) weight loss in percent
(8) sex
(9) age group
Parameter
Finding
Points
Stage
I
0
II
2
IIIA
5
IIIB
7
IV
9
histologic type
NSCLC NOS
3
adeno, squamous, large cell
0
proven actionable mutation
no
3
yes
0
unknown
0
ECOG performance
0 or 1
0
2 to 4
3
smoking history
never
0
previous
2
current
2
respiratory comorbidity
no
0
yes
2
weight loss
<= 10%
0
> 10%
2
sex
female
0
male
1
age group
<= 50 years
0
51 to 70 years
1
71 to 90 years
2
>= 91 years
3
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 28
Total Score
LCPI Group
2-Year Overall Survival (Derivation Cohort)
<= 9
1
84%
10 to 13
2
61%
14 to 16
3
33%
>= 17
4
7%
Performance:
• The area under the ROC curve is 0.74 in the derivation cohort.
To read more or access our algorithms and calculators, please log in or register.
